Non-alcoholic fatty liver disease (NAFLD) is a growing health concern in the global medical community. With rising prevalence, understanding its pathophysiology and the need for proactive management is critical for healthcare professionals.
NAFLD, characterized by excess fat accumulation in the liver unrelated to alcohol consumption, is now the most common chronic liver disease worldwide. It affects approximately 25% of the global population, with higher prevalence in individuals with type 2 diabetes and obesity.
The pathogenesis of NAFLD is complex and multifactorial, typically described by the 'two-hit' hypothesis. The 'first hit' involves the accumulation of lipids in the liver, leading to steatosis. The 'second hit' is characterized by inflammation, oxidative stress, and fibrogenesis, leading to the progression of NAFLD to non-alcoholic steatohepatitis (NASH), fibrosis, and potentially cirrhosis and hepatocellular carcinoma.
Proactive management of NAFLD involves early detection, lifestyle modifications, and pharmacological interventions. Screening high-risk populations, such as those with obesity and type 2 diabetes, is crucial for early detection. Lifestyle modifications, including weight loss, healthy diet, and regular exercise, are the first-line treatment. Pharmacological interventions are typically reserved for patients with NASH and significant fibrosis. Emerging therapies targeting various aspects of NAFLD pathogenesis are under investigation.
NAFLD is a significant global health concern with complex pathophysiology. Proactive management, including early detection and lifestyle modifications, is essential to prevent disease progression. Further research is needed to develop effective pharmacological therapies. Healthcare professionals play a vital role in the management of this disease, necessitating a comprehensive understanding of NAFLD.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation